Document ID: chunk:federal_register_of_legislation:F2023L01748:schedule:1
Version: federal_register_of_legislation:F2023L01748
Segment Type: schedule
Provision Reference: sch 1
Character Range: 2173–3469

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
    [1]           Schedule 1, after entry for Acalabrutinib in the form Tablet 100 mg [Maximum Quantity: 56; Number of Repeats: 5]
    insert:
      20  56  6

    [2]           Schedule 1, entry for Moxonidine in the form Tablet 400 micrograms
         omit:
      20  60  5

    [3]           Schedule 1, entry for Nicorandil in the form Tablets 10 mg, 60
         omit:
      20  2  5

    [4]           Schedule 1, entry for Nicorandil in the form Tablets 20 mg, 60
         omit:
      20  2  5

    [5]           Schedule 1, entry for Pravastatin
         substitute:
Pravastatin  Tablet containing pravastatin sodium 10 mg  20  30  5
             Tablet containing pravastatin sodium 20 mg  20  30  5
             Tablet containing pravastatin sodium 40 mg  20  30  5
             Tablet containing pravastatin sodium 80 mg  20  30  5

    [6]           Schedule 2, after entry for Moxonidine in the form Tablet 200 micrograms
         insert:
   Tablet 400 micrograms  50  60  5

    [7]           Schedule 2, after entry for Nebivolol in the form Tablet 10 mg (as hydrochloride)
         insert:
Nicorandil  Tablets 10 mg, 60  50  2  5
            Tablets 20 mg, 60  50  2  5